Welsh health data company Aparito were represented at the UK wide AXA 2018 Health Tech & You awards ceremony held on the 9th May 2018 at the headquarters of the Royal College of General Practitioners in London. The company who were established in 2014 were joint winners of the Health Tech & You award for early diagnosis of dementia. Dr Elin Haf Davies, Aparito’s founder and Chief Executive Officer who hails from Bala but now lives in London, collected the award for the company’s proposal using a machine learning platform to monitor changes in sleep, activity, voice, ADL and memory collectively.
Aparito are proposing a platform that provides wearable devices and disease-specific mobile apps to provide remote patient monitoring outside of the hospital environment. This continued monitoring provides real-time data for clinicians to capture subtle differences in ambulation and sleeping patterns, which can’t be conveyed during short, snapshot clinic visits, in a way that actively supports and enhances diagnosis, treatment and drug development. Aparito is also developing a tool which can measure differences in speech patterns. Elin said following her success “it’s a real achievement for us and we are so proud of the innovative team who have been working so hard to develop the technology”. “Aparito are going from strength to strength with a number of projects in development and a study taking place over the next few weeks in South Africa”. This week’s awards success caps off a remarkable 18 months for the Wrexham Technology business park start up. In December Aparito won the title of 'Best Startup' at the Mediwales Innovation Awards 2017. Elin spent much of her time as a paediatric nurse caring for children with rare diseases. She conducted redundant, time consuming, and often painful tests in order to monitor each patient's health. After feeling this method was inefficient Elin came up with the idea of remote patient realtime monitoring. With the help of a team of diverse backgrounds, Aparito was born. Together we share the goal of improving the lives of individuals with rare diseases.